Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 1998
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Key products include EPOGEN (Epoetin alfa), NEUPOGEN (Filgrastim), and INFERGEN (Interferon alfacon-1).
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 1998 |
Six Months Ended June 30, 1998 |
|---|---|---|
| Total Revenues | $656.9 | $1,262.3 |
| Net Income | $216.3 | $403.6 |
| Earnings Per Share (Diluted) | $0.82 | $1.53 |
| Operating Cash Flow (6mo) | N/A | $515.0 |
| Cash & Cash Equivalents | $158.0 | $158.0 |
| Total Debt (Short & Long Term) | $234.0 | $234.0 |
| Cost of Sales Margin | 13.7% | 13.8% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 6% for the three months and 6% for the six months ended June 30, 1998, compared to the same periods in 1997. Product sales grew 8% (quarterly) and 7% (year-to-date).
- Profitability: Net income rose 8% quarterly ($216.3M vs. $200.5M) and 6% year-to-date ($403.6M vs. $380.8M). Diluted EPS increased from $0.72 to $0.82 (quarterly) and $1.37 to $1.53 (year-to-date).
- Product Performance:
- EPOGEN: Sales increased 14% quarterly and 9% year-to-date, driven by growth in the U.S. dialysis population and higher dosing due to revised HCFA reimbursement policies.
- NEUPOGEN: Sales decreased 0.4% quarterly but increased 3% year-to-date. Growth was offset by declines in off-label AIDS usage, unfavorable foreign currency effects, and EU market slowdowns.
- Corporate Partner Revenues: Decreased 25% quarterly and 22% year-to-date, primarily due to a $20M milestone payment received in Q2 1997 that did not recur.
- Expenses: R&D expenses increased 5% quarterly and 4% year-to-date due to higher clinical and preclinical costs. Marketing and selling expenses decreased 9% and 6% respectively, aided by lower arbitration-related costs.
- Tax Rate: The effective tax rate increased to 30.0% from 28.0% due to federal tax law changes capping benefits for Puerto Rico operations.
Guidance, Outlook, and Risks
Management Outlook
- 1998 Sales Growth: Amgen anticipates total product sales growth at or close to a double-digit rate. EPOGEN is expected to grow at a low double-digit rate, while NEUPOGEN is expected to grow at a low single-digit rate.
- Expenses: R&D expenses for 1998 are projected to be approximately $650 million. Marketing and G&A expenses are expected to have little growth.
- Earnings: EPS for 1998 is expected to grow at a low double-digit rate, excluding the impact of the 1997 legal assessment.
Key Risks and Contingencies
- Johnson & Johnson Arbitration: Ongoing disputes regarding "spillover" sales of EPOGEN/PROCRIT. While Amgen was successful in a recent arbitration ruling regarding audit methodology, J&J has challenged audit results for 1995-1997. Amgen has also filed a demand to terminate J&J's license rights. The outcome remains uncertain, though management does not expect a material adverse effect on annual statements.
- Biogen Litigation: Biogen alleges patent infringement regarding NEUPOGEN and INFERGEN. The court has limited the scope of Biogen's patent claims, but the case is ongoing with no trial date set.
- Securities Litigation: Class action lawsuits filed in August 1998 alleging false statements regarding sales growth and arbitration proceedings. Amgen has not yet reviewed the complaints.
- Reimbursement Policy: EPOGEN sales are sensitive to HCFA reimbursement policies. Recent revisions (March and June 1998) eased restrictions, but the timing of provider adoption remains unpredictable.
- Year 2000 Compliance: The company is assessing computer systems for Y2K compliance. Failure of key third-party businesses to comply could materially affect operations.
Investor Verification Checklist
- Arbitration Status: Verify the final resolution of the Johnson & Johnson arbitration regarding 1995-1997 audit results and the potential termination of the license agreement.
- HCFA Impact: Monitor the actual implementation of June 1998 HCFA reimbursement revisions by dialysis providers and fiscal intermediaries to confirm EPOGEN growth projections.
- NEUPOGEN Market Dynamics: Assess the continued impact of protease inhibitors on off-label AIDS usage and the competitive landscape in the EU.
- Legal Exposure: Review developments in the Biogen patent litigation and the newly filed securities class action lawsuits.
- Capital Allocation: Confirm the pace of the $1 billion stock repurchase program (with $255M remaining as of June 30, 1998) and capital expenditure plans ($400M-$500M for 1998).